https://www.avient.com/sites/default/files/resources/POL%2520KeyBanc%2520IR%2520Presentation%2520w%2520non-GAAP%252009%252010%25202013.pdf
Use of Non GAAP Measures Page 3 -150.00% -50.00% 50.00% 150.00% 250.00% 350.00% PolyOne S&P 500 Strategy and Execution Drive Results Page 4 All time closing high of $29.48 August 1, 2013 • 15 consecutive quarters of double digit EPS growth • 42% CAGR adjusted EPS expansion 2006-2012 • YTD stock price has increased 42% versus 20% growth in the S&P • 275% increase in market cap: $0.7b $2.6b since 2006 The World’s Premier Provider of Specialized Polymer Materials, Services & Solutions Four Pillar Strategy Page 5 PP&S 15% Specialty 60% Distribution 25% 0.12 0.27 0.21 0.13 0.68 0.82 1.00 2.50 $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 $1.50 $1.75 $2.00 $2.25 $2.50 2006 2007 2008 2009 2010* 2011* 2012* 2015 Target Ad ju st ed E ar ni ng s P er S ha re Appliance 6% Building & Construction 13% Wire & Cable 9% Electrical & Electronics 4% Consumer 9% Packaging 18% Industrial 10% Misc. 5% HealthCare 9% Transportation 16% Textiles 1% United States 70% Europe 14% Canada 8% Asia 5% Latin America 3% 2012 Revenues: $4.0 Billion* End Markets* 2012 Revenues: $4.0 Billion* EPS Page 6 * Pro Forma includes FY2012 results for Spartech (11/03/12 YE) and Glasforms & excludes discontinued operations PolyOne At A Glance * Restated to exclude discontinued operations Old PolyOne Transformation *Operating Income excludes corporate charges and special items **Pro Forma results include Spartech and Glasforms acquisitions, Specialty Coatings reclass and excludes discontinued operations 2% 34% 43% 45% 60% 65- 75% 0% 20% 40% 60% 80% 100% 2005 2008 2010 2012 2012 PF** 2015 % o f O pe ra tin g In co m e* JV's PP&S Distribution Specialty Specialty OI $5M $46M $87M $114M $150M Target Mix Shift Highlights Specialty Transformation 2015 Target Page 7 2006 H1 2013 2015 Where we were Where we are Organic Consolidated Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 12.7% 12.6% 12 – 16% Global Specialty Engineered Materials 1.1% 10.9% 9.2% 12 – 16% Designed Structures & Solutions — — 4.4% 8 – 10% Performance Products & Solutions 5.4% 8.1% 8.2% 9 – 12% Distribution 2.6% 6.1% 6.1% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 62% 65 – 75% 3) ROIC* (after-tax) 5.0% 9.4% 15% 4) Adjusted EPS Growth N/A 26% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 8 *Percentage of Specialty Platform revenue from products introduced in last five years 19.5% 46.5% 2006 Q2 2013 $20.3 $44.7 2006 TTM Q2'13 14.3% 31.1% 2006 Q2 2013 Research & Development Spending Specialty Platform Vitality Index Progression* Innovation Drives Earnings Growth ($ millions) Specialty Platform Gross Margin % Page 9 We are Experts in Polymer Science and Formulation Polymer Science Formulation Chemistry Processing Inputs Base Resins Additives Modifiers Colorants Specialized Polymer Materials, Services, and Solutions Expertise Satisfied Consumers PolyOne Customer Innovative Products & Services Marketplace Demands Performance Requirements Value Drivers Page 10 Positioned for Strong Growth 2015 Target Rev: $5B Adj.
EPS: $2.50 Assumptions • Operating margins in mid-range of 2015 targets • No global recession • No investment in incremental PP&S capacity • Completion of 2-3 midsize accretive acquisitions • Housing starts at 85% of 50 year norm by 2015 • Mid single digit revenue CAGR • Remain comfortably below 3X Net Debt / EBITDA Page 11 2012 Rev: $2.9B Adj.
https://www.avient.com/sites/default/files/resources/POL%2520BofA%2520Basic%2520Materials%2520IR%2520Presentation%2520w%2520non-GAAP%252012%252011%25202013.pdf
Use of Non-GAAP Measures Page 3 -150.00% -50.00% 50.00% 150.00% 250.00% 350.00% PolyOne S&P 500 All time high of $34.47 December 9th, 2013 • 16 consecutive quarters of double digit EPS growth • 42% CAGR adjusted EPS expansion 2006-2012 • YTD stock price has increased 63% versus 27% growth in the S&P • More than six fold increase in market cap: $0.5b $3.3b Strategy and Execution Drive Results Page 4 The World’s Premier Provider of Specialized Polymer Materials, Services & Solutions Four Pillar Strategy Page 5 PP&S 15% Specialty 60% Distribution 25% 0.12 0.27 0.21 0.13 0.68 0.82 1.00 2.50 $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 $1.50 $1.75 $2.00 $2.25 $2.50 2006 2007 2008 2009 2010* 2011* 2012* 2015 Target Ad ju st ed E ar ni ng s P er S ha re Appliance 6% Building & Construction 13% Wire & Cable 9% Electrical & Electronics 4% Consumer 9% Packaging 18% Industrial 10% Misc. 5% HealthCare 9% Transportation 16% Textiles 1% United States 70% Europe 14% Canada 8% Asia 5% Latin America 3% 2012 Revenues: $4.0 Billion* End Markets* 2012 Revenues: $4.0 Billion* EPS Page 6 * Pro Forma includes FY2012 results for Spartech (11/03/12 YE) and Glasforms & excludes discontinued operations PolyOne At A Glance * Restated to exclude discontinued operations Old PolyOne Transformation *Operating Income excludes corporate charges and special items 2% 34% 43% 63% 65- 75% 0% 20% 40% 60% 80% 100% 2005 2008 2010 YTD 2013 2015 % o f O pe ra tin g In co m e* JV's PP&S Distribution Specialty Specialty OI $5M $46M $87M $153M Target Mix Shift Highlights Specialty Transformation 2015 Target Page 7 2006 YTD 2013 2015 Where we were Where we are Organic Consolidated Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 12.8% 12.8% 12 – 16% Global Specialty Engineered Materials 1.1% 10.8% 8.9% 12 – 16% Designed Structures & Solutions — — 5.0% 8 – 10% Performance Products & Solutions 5.5% 8.0% 8.2% 9 – 12% Distribution 2.6% 6.1% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 63% 65 – 75% 3) ROIC* (after-tax) 5.0% 9.4% 15% 4) Adjusted EPS Growth N/A 28% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 8 *Percentage of Specialty Platform revenue from products introduced in last five years 19.5% 44.0% 2006 Q3 2013 $20.3 $46.6 2006 TTM Q3'13 14.3% 31.0% 2006 Q3 2013 Research & Development Spending Specialty Platform Vitality Index Progression* Innovation Drives Earnings Growth ($ millions) Specialty Platform Gross Margin % Page 9 We are Experts in Polymer Science and Formulation Polymer Science Formulation Chemistry Processing Inputs Base Resins Additives Modifiers Colorants Specialized Polymer Materials, Services, and Solutions Expertise Satisfied Consumers PolyOne Customer Innovative Products & Services Marketplace Demands Performance Requirements Value Drivers Page 10 Positioned for Strong Growth 2015 Target Rev: $5B Adj.
EPS: $2.50 Assumptions • Mid single digit revenue CAGR • Operating margins in mid-range of 2015 targets • No global recession • No investment in incremental PP&S capacity • Housing starts at 85% of 50 year norm by 2015 • Remain comfortably below 3X Net Debt / EBITDA Page 11 2012 Rev: $2.9B Adj.
https://www.avient.com/sites/default/files/Amy Evins Bio 2023.pdf
Prior to LPL Financial, she held CIO roles at Tenet Healthcare and Conifer Health Solutions.
https://www.avient.com/sites/default/files/2021-04/gravi-tech-pipe-system-valve-case-study.pdf
In addition, to make brass machinable, lead is typically added, introducing environmental and health risks.
THE IMPACT Gravi-Tech high-density formulations enabled API to design and mold a patented, full-opening flapper valve that is not only unique in the market, but also offers important cost, performance and environmental advantages over brass.. • System cost reduction = competitive advantage: The PolyChek valve featuring Gravi-Tech materials offer customers faster installation, less maintenance and longer life. • Design freedom = unique product offering: The ability to injection mold Gravi-Tech materials instead of machining brass enabled API to design a cost-effective, full-opening flapper valve that is 100% pigable. • High performance = customer satisfaction: The PolyChek valve gives API’s customers the ability to create all-plastic piping systems that eliminate leakage and weak spots. • Elimination of lead = increased safety and compliance: Replacing brass with Gravi-Tech high-density formulations eliminates health and safety concerns about lead. • Use of existing tooling = lower capital costs: API was able to use the same mold originally designed for nylon to run the Gravi-Tech materials, saving the substantial costs of retooling.
https://www.avient.com/sites/default/files/2022-05/Glucose Monitoring App Snapshot.pdf
Glucose Monitoring App Snapshot draft MEDICAL DEVICE OEM C O N T I N U O U S G L U C O S E M O N I T O R I N G S Y S T E M • Adapt to strict processing requirements of a secondary operation put in place to manufacture a new device model • Meet material size and thickness requirements while achieving desired color target • Overcome material unpredictability and sensitivity to heat, light and moisture • Minimize impact of supply chain instability and changes • Offered support for processing under low pressure conditions and at every stage of manufacturing • Performed extensive R&D work to consistently deliver the customer’s color target of a hard-to-achieve light gray • Effectively addressed all material challenges and sensitivities • Provided regular ‘summaries of understanding’ to keep up with changing forecasts and ordering patterns Mevopur™ Pre-color Formulation KEY REQUIREMENTS WHY AVIENT?
https://www.avient.com/sites/default/files/2021-07/mevopur-needle-hub-1-page-case-study.pdf
NEEDLE HUB MANUFACTURER N E E D L E H U B C O L O R S • RAL and Pantone® colors available in palette to align with ISO 6009 color standard • Opaque and transparent polypropylene selections available in both masterbatch and ready-to-use precolors • Raw materials pre-tested to ISO 10993 and USP Class VI medical device guidelines • Certified formulations available globally • Provided RAL and Pantone colors as required • Developed custom polypropylene formulations to meet specific opacities • Offered pre-tested raw materials and produced in an ISO 13485 certified site, minimizing risk across the value chain • Provided global formulations transferrable from our three ISO 13485 certified facilities Mevopur™ Healthcare Colors KEY REQUIREMENTS WHY AVIENT?
https://www.avient.com/sites/default/files/2023-09/65567-Certificate-08SEP2023.pdf
MANUFACTURE OF COLORANTS FOR PLASTICS FOR THE MEDICAL DEVICE INDUSTRY Certificate Of Conformance
https://www.avient.com/sites/default/files/2022-09/54139-Certificate-29AUG2022%5B98%5D.pdf
COMPOUND, SUPPLY AND PROTOTYPING SERVICES OF THERMOPLASTICS FOR THE MEDICAL DEVICE INDUSTRY Certificate Of Conformance
https://www.avient.com/sites/default/files/resources/NEU%2520ISO%25209001-2015%2520Exp%25201-22%2520%25281%2529.pdf
COMPOUND AND SUPPLY OF THERMOPLASTICS FOR THE MEDICAL DEVICE INDUSTRY.
https://www.avient.com/sites/default/files/resources/Polyone%2520AR.pdf
Health and wellness is a commitment we make to every PolyOne associate.
At our Investor Day in May of last year, we communicated a path to achieving sustainable double digit annual adjusted EPS growth and 16–17% Return on Invested Capital (ROIC).
Environmental, Health and Safety 4.